HeyJaredJonathan Goodman
- Indexed articles, last 90 days
- 11
- Latest publication
- Oct 1, 2026
- Outlet visibility, for Cancer Therapy Advisor
- Top 5M sites
- Earliest in this view
- Jul 23, 2026
Latest articles
Mosunetuzumab Plus Polatuzumab Vedotin Safe and Effective in Relapsed or Refractory MCL - Oncology Nurse Advisor (opens the original)
Read excerpt
A fixed-term regimen of mosunetuzumab plus polatuzumab vedotin may be safe and effective among patients with relapsed or refractory mantle cell lymphoma (MCL) following Bruton tyrosine kinase (BTK) inhibitor therapy, according to research published in Blood. While cytokine release syndrome (CRS) occurred in 43% of patients, all cases were grade 1 or 2, the authors added. Patients with high-risk biological and clinical features, such as relapse following multiple lines of treatment including BTK
Mosunetuzumab Plus Polatuzumab Vedotin Safe and Effective in Relapsed or Refractory MCL (opens the original)
Read excerpt
A fixed-term regimen of mosunetuzumab plus polatuzumab vedotin may be safe and effective among patients with relapsed or refractory mantle cell lymphoma (MCL) following Bruton tyrosine kinase (BTK) inhibitor therapy, according to research published in Blood. While cytokine release syndrome (CRS) occurred in 43% of patients, all cases were grade 1 or 2, the authors added. Patients with high-risk biological and clinical features, such as relapse following multiple lines of treatment including BTK
Low-Dose Nivolumab Plus AVD Shows High Response Rate at a Lower Cost in HL (opens the original)
Read excerpt
Among patients with classical Hodgkin lymphoma (HL), first-line low-dose nivolumab combined with doxorubicin, vinblastine, and dacarbazine (N-AVD) yields high response rates at a fraction of the cost of conventional therapeutic strategies, according to research presented at the Society of Hematology Oncology 2026 Annual Meeting. The study authors noted that total drug costs were 75% lower than with standard nivolumab dosage, and suggested that N-AVD may therefore be feasible in settings where re
Low-Dose Nivolumab Plus AVD Shows High Response Rate at a Lower Cost in HL - Oncology Nurse Advisor (opens the original)
Read excerpt
Among patients with classical Hodgkin lymphoma (HL), first-line low-dose nivolumab combined with doxorubicin, vinblastine, and dacarbazine (N-AVD) yields high response rates at a fraction of the cost of conventional therapeutic strategies, according to research presented at the Society of Hematology Oncology 2026 Annual Meeting. The study authors noted that total drug costs were 75% lower than with standard nivolumab dosage, and suggested that N-AVD may therefore be feasible in settings where re
Pirtobrutinib-Based Triplet Combination Shows Promise in CLL (opens the original)
Read excerpt
A first-line combination of pirtobrutinib plus venetoclax and obinutuzumab shows a high rate of response among patients with chronic lymphocytic leukemia (CLL), according to research presented at the Society of Hematology Oncology 2026 Annual Meeting. While the rate of grade 3 or 4 neutropenia is common, the drug combination nonetheless shows promise in this patient population, noted Nitin Jain, MD, of the Department of Leukemia at the University of Texas MD Anderson Cancer Center in Houston, wh
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 5M sites
For Cancer Therapy Advisor, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.